Breaking News Instant updates and real-time market news.

OLED

Universal Display

$109.00

-15 (-12.10%)

, OKE

Oneok

$57.87

1.4 (2.48%)

10:35
03/20/18
03/20
10:35
03/20/18
10:35

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Universal Display (OLED) upgraded to Buy from Hold at Gabelli with analyst Hendi Susanto saying he views the negative market response to a Bloomberg report that Apple (AAPL) is designing and producing MicroLED display prototypes as an overreaction and a buying opportunity. 2. Oneok (OKE) upgraded to Buy from Hold at Jefferies with analyst Christopher Sighinolfi saying he is confident in Oneok's ability to hit target returns on $4.2B of its current projects following a recent meeting with management. 3. PPG (PPG) upgraded to Buy from Hold at Deutsche Bank with analyst David Begleiter saying he believes the company's capital deployment and "valuation discount" are attractive. 4. Roku (ROKU) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein upgraded Roku (ROKU) to Perform citing valuation and the company's opportunity in virtual multichannel video programming distribution. 5. Arena Pharmaceuticals (ARNA) upgraded to Buy from Hold at Needham with analyst Alan Carr citing the company's "impressive results" from its Phase 2 Ulcerative Colitis study, noting that the the safety and tolerability data components are also "encouraging." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

OLED

Universal Display

$109.00

-15 (-12.10%)

OKE

Oneok

$57.87

1.4 (2.48%)

PPG

PPG

$114.42

1.2 (1.06%)

ROKU

Roku

$33.85

-2.01 (-5.61%)

ARNA

Arena Pharmaceuticals

$30.89

-0.62 (-1.97%)

  • 20

    Mar

  • 21

    Mar

  • 03

    Apr

  • 23

    May

OLED Universal Display
$109.00

-15 (-12.10%)

03/20/18
GABE
03/20/18
UPGRADE
GABE
Buy
Universal Display upgraded to Buy from Hold at Gabelli
Gabelli analyst Hendi Susanto upgraded Universal Display (OLED) to Buy from Hold, as he views the negative market response to a Bloomberg report that Apple (AAPL) is designing and producing MicroLED display prototypes as an overreaction and a buying opportunity. He believes that it is premature to have conviction that MicroLED, which Apple is working on, has reached a stage where it will be a formidable competing display technology to organic LEDs, or OLED, and active matrix OLED, or AMOLED, displays.
02/20/18
COWN
02/20/18
NO CHANGE
Target $225
COWN
Outperform
Strong finish by Samsung should drive Universal Display results, says Cowen
Cowen analyst Robert Stone noted Samsung (SSNLF) had a strong finish to 2017, which he sees as suggesting upside to Q4 results for Universal Display (OLED) shares. The analyst expects Universal's Q4 to be above consensus driven by Samsung's strong flexible AMOLED shipments. He also sees further penetration of Samsung branded products, at least two new iPhone models, and mobile capacity ramping by LG Display. Stone reiterated his Outperform rating and $225 price target on Universal Display shares.
02/20/18
02/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Sell at Stifel with analyst Chris O'Cull saying that his opinion of the company's fundamentals has not changed, but sentiment has improved and he believes investor optimism will likely outweigh fundamentals in the near-term. 2. Hyatt (H) and Marriott (MAR) were upgraded to In Line from Underperform at Evercore ISI. 3. Flowserve (FLS) upgraded to Sector Perform from Underperform at RBC Capital with analyst Deane Dray citing his expectations of an announcement of a turnaround plan from the new CEO and believes the stock may have bottomed, since the fourth quarter operating miss and "low-balled fiscal 2018 outlook" did not produce new selling pressure. 4. UPS (UPS) upgraded to Buy from Hold at Edward Jones. 5. Universal Display (OLED) upgraded to Buy from Hold at Needham with analyst James Ricchiuti saying he has been looking for the right entry point on the stock since the summer, and the recent 25% selloff from the high offers that opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/18
NEED
02/20/18
UPGRADE
Target $180
NEED
Buy
Universal Display upgraded to Buy at Needham on valuation
As reported earlier, Needham analyst James Ricchiuti upgraded Universal Display (OLED) to Buy from Hold with a $180 price target. The analyst says that he has been looking for the right entry point on the stock since the summer, and the recent 25% selloff from the high offers that opportunity. While expectations for Q4 results this week are more cautious amid the anxiousness around the Samsung (SSNLF) and Apple (AAPL) ramp, the positives of the new Samsung license agreement in hand and capacity ramping in Korea and China over the next two years outweigh the concerns.
OKE Oneok
$57.87

1.4 (2.48%)

01/16/18
RBCM
01/16/18
UPGRADE
Target $68
RBCM
Outperform
Oneok upgraded to Outperform at RBC Capital on Williston Basin exposure
As reported earlier, RBC Capital analyst Elvira Scotto upgraded Oneok to Outperform from Sector Perform and raised her price target to $68 from $57. Scotto cites an "attractive asset footprint", particularly in the Williston Basin, as well as the company's mainly "fee-based cash flow". The analyst expects Oneok to generate EBITDA growth of about 40% from 2017 to 2020 with "minimal to no equity needs".
03/20/18
JEFF
03/20/18
UPGRADE
Target $67
JEFF
Buy
Oneok upgraded to Buy from Hold at Jefferies
Jefferies analyst Christopher Sighinolfi upgraded Oneok to Buy and raised his price target for the shares to $67 from $56. The analyst also added the stock to his firm's Franchise Picks List. The analyst is confident in Oneok's ability to hit target returns on $4.2B of its current projects following a recent meeting with management. He sees a path to 10% annual earnings growth through 2020.
03/15/18
EVER
03/15/18
NO CHANGE
EVER
Evercore ISI says FERC rule shouldn't impact Kinder Morgan, Enbridge pipelines
After FERC said it no longer will allow master limited partnership interstate natural gas and oil pipelines to recover an income tax allowance in cost of service rates, Evercore ISI analyst Timm Schneider said he does not expect pipelines owned by C-Corps, such as Kinder Morgan (KMI), Oneok (OKE), Enbridge (ENB) and TransCanada (TRP), to be impacted. The proposed change is likely to impact MLPs with large amounts of "cost of service" exposure, such as those with large amounts of interstate gas pipelines, like Williams (WMB) and Tallgrass (TEP; TEGP), he said. Overall the selloff across the sector is likely overstated, added Schneider.
01/17/18
LEHM
01/17/18
UPGRADE
Target $67
LEHM
Overweight
Oneok upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Christine Cho upgraded Oneok to Overweight and raised her price target for the shares to $67 from $58. The analyst realigned her ratings in the space to favor commodity and volume exposure.
PPG PPG
$114.42

1.2 (1.06%)

01/17/18
ATLE
01/17/18
DOWNGRADE
Target $125
ATLE
Neutral
PPG downgraded to Neutral at Atlantic Equities
As previously reported, Atlantic Equities downgraded PPG to Neutral from Overweight and raised its price target to $125 from $115. Analyst Colin Isaac said earnings momentum stalled in 2017 and expects lower growth in 1H 2018 due to timing of buybacks, raw material costs, and more difficult comps.
01/17/18
ATLE
01/17/18
DOWNGRADE
ATLE
Neutral
PPG downgraded to Neutral from Overweight at Atlantic Equities
01/19/18
JPMS
01/19/18
DOWNGRADE
Target $120
JPMS
Neutral
PPG downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded PPG Industries (PPG) to Neutral with an unchanged price target of $120 citing valuation. The analyst no longer believes a merger with AkzoNobel (AKZOY) is likely for 2018 and doesn't find the stock's current free cash flow yield "particularly alluring."
03/20/18
DBAB
03/20/18
UPGRADE
Target $130
DBAB
Buy
PPG upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst David Begleiter upgraded PPG Industries to Buy and raised his price target for the shares to $130 from $126. The analyst believes the company's capital deployment and "valuation discount" are attractive.
ROKU Roku
$33.85

-2.01 (-5.61%)

02/22/18
RBCM
02/22/18
NO CHANGE
Target $45
RBCM
Sector Perform
Roku price target raised to $45 from $28 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Roku to $45 after the company's Q4 results, saying the adjusted EBITDA was well above consensus while the EBITDA margin of 8% was a record high. Mahaney adds that Q4 fundamentals were strong, with very slight deceleration in platform revenue growth and overall margin expansion. Mahaney keeps his Sector Perform rating on Roku.
02/22/18
NEED
02/22/18
NO CHANGE
Target $50
NEED
Strong Buy
Needham says buy Roku amid 18% selloff given discount to Netflix
Needham analyst Laura Martin recommends using the post-earnings selloff in shares of Roku (ROKU) as a buying opportunity. The stock in premarket trading is down 18%, or $9.40, to $41.90. Martin keeps a Buy rating on the shares with a $50 price target. The stock will open lower based on a non-cash accounting change to Accounting Standards Codification 606 that lowers Roku's projected gross profit, adjusted EBITDA and earnings, Martin tells investors in a research note. The analyst, however, expects ASC 606 to elevate Roku's reported revenue and costs, which she feels is helpful, noting the stock likely trades on a multiple of forward revenue. At 7.0 times, Roku trades at a "sharp discount" to its closest comp, Netflix (NFLX), which trades at 10.7 times, Martin contends. She thinks investors should own Roku given the "steep discount" to Netflix despite "comparable growth credentials, a better margin profile, lower content risks, and little competitive threat from new OTT channel launches."
03/20/18
OPCO
03/20/18
UPGRADE
OPCO
Perform
Roku upgraded to Perform from Underperform at Oppenheimer
Oppenheimer analyst Jason Helfstein upgraded Roku to Perform citing valuation and the company's opportunity in virtual multichannel video programming distribution.
03/20/18
OPCO
03/20/18
UPGRADE
OPCO
Perform
Roku no longer looks like 'compelling short,' Opco says in upgrade
Oppenheimer analyst Jason Helfstein upgraded Roku to Perform from Underperform saying the stock "no longer appears to be a compelling short." Shares have declined to $34 from a peak of $57, Helfstein tells investors in a research note. He sees Roku's risk/reward as "neutral to favorable," noting the company's 2018 guidance now reflects the negative impact of new accounting standard ASC 606. The Roku Channel being pulled forward to 2018, marketing dollars associated with the acceleration of skinny bundle adoption and potential automatic content recognition monetization represent potential positive catalysts, Helfstein writes. He does not have a price target on the shares. Roku in premarket trading is up 5%, or $1.60, to $35.45.
ARNA Arena Pharmaceuticals
$30.89

-0.62 (-1.97%)

03/20/18
JMPS
03/20/18
NO CHANGE
Target $79
JMPS
Outperform
Arena Pharmaceuticals price target raised to $79 from $63 at JMP Securities
JMP Securities analyst Jason Butler said Arena Pharmaceuticals' top-line results for etrasimod in ulcerative colitis meet or beat his best-case expectations and he has increased his view of the probability of success for etrasimod in UC to 75% from 50% following the report of the data. Given the higher odds he places on the success of the drug in that indication, Butler raised his price target on Arena shares to $79 from $63 and keeps an Outperform rating on the stock.
03/20/18
NEED
03/20/18
UPGRADE
Target $60
NEED
Buy
Arena Pharmaceuticals upgraded to Buy at Needham on phase 2 UC data
As reported earlier, Needham analyst Alan Carr upgraded Arena Pharmaceuticals to Buy from Hold with a price target of $60. Carr cites the company's "impressive results" from its Phase 2 Ulcerative Colitis study unveiled yesterday, noting that the the safety and tolerability data components are also "encouraging". The analyst adds that the favorable outcome warrants an update to his pricing model, particularly in light of "substantial" unmet need in the Inflammation space where there are few S1P modulators currently in development.
03/20/18
WELS
03/20/18
NO CHANGE
Target $60
WELS
Outperform
Arena Pharmaceuticals price target raised to $60 from $53 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Arena Pharmaceuticals to $60 form $53 following positive OASIS phase 2 data for etrasimod in ulcerative colitis. The analyst reiterates an Outperform rating on the shares.
03/20/18
NEED
03/20/18
UPGRADE
NEED
Buy
Arena Pharmaceuticals upgraded to Buy from Hold at Needham

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.